Design Therapeutics IncNASDAQ:DSGN
- LAST PRICE5.5700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.0100/ 1
- Ask / Lots6.0000/ 2
- Open / Previous Close--- / 5.5700
- Day Range---
- 52 Week Range
- Volume1
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DSGN |
|---|---|---|
| 09:32 ET | 609 | 5.65 |
| 09:39 ET | 300 | 5.495 |
| 09:48 ET | 100 | 5.485 |
| 09:50 ET | 100 | 5.475 |
| 09:51 ET | 200 | 5.52 |
| 10:06 ET | 100 | 5.55 |
| 10:08 ET | 650 | 5.555 |
| 10:09 ET | 200 | 5.545 |
| 10:13 ET | 200 | 5.57 |
| 10:20 ET | 100 | 5.63 |
| 10:24 ET | 300 | 5.61 |
| 10:31 ET | 6440 | 5.56 |
| 10:33 ET | 200 | 5.565 |
| 10:36 ET | 1100 | 5.62 |
| 10:38 ET | 1838 | 5.67 |
| 10:40 ET | 100 | 5.66 |
| 10:42 ET | 100 | 5.66 |
| 10:45 ET | 100 | 5.705 |
| 10:56 ET | 600 | 5.6953 |
| 11:00 ET | 700 | 5.66 |
| 11:02 ET | 100 | 5.66 |
| 11:03 ET | 380 | 5.65 |
| 11:05 ET | 400 | 5.625 |
| 11:07 ET | 100 | 5.59 |
| 11:09 ET | 200 | 5.59 |
| 11:12 ET | 200 | 5.585 |
| 11:14 ET | 100 | 5.57 |
| 11:16 ET | 200 | 5.61 |
| 11:18 ET | 100 | 5.56 |
| 11:21 ET | 400 | 5.56 |
| 11:23 ET | 281 | 5.53 |
| 11:25 ET | 824 | 5.5799 |
| 11:27 ET | 100 | 5.555 |
| 11:30 ET | 100 | 5.54 |
| 11:32 ET | 200 | 5.54 |
| 11:34 ET | 200 | 5.54 |
| 11:38 ET | 400 | 5.56 |
| 11:39 ET | 200 | 5.53 |
| 11:41 ET | 100 | 5.53 |
| 11:43 ET | 100 | 5.52 |
| 11:50 ET | 100 | 5.55 |
| 12:01 ET | 355 | 5.57 |
| 12:12 ET | 300 | 5.54 |
| 12:15 ET | 100 | 5.55 |
| 12:26 ET | 500 | 5.59 |
| 12:37 ET | 100 | 5.62 |
| 12:42 ET | 1000 | 5.5963 |
| 12:46 ET | 100 | 5.6 |
| 12:48 ET | 100 | 5.6 |
| 12:51 ET | 100 | 5.57 |
| 12:55 ET | 400 | 5.6 |
| 01:06 ET | 200 | 5.58 |
| 01:22 ET | 219 | 5.575 |
| 01:24 ET | 300 | 5.575 |
| 01:29 ET | 300 | 5.58 |
| 01:36 ET | 118 | 5.57 |
| 01:38 ET | 100 | 5.57 |
| 01:42 ET | 200 | 5.54 |
| 01:51 ET | 100 | 5.55 |
| 01:56 ET | 600 | 5.52 |
| 02:05 ET | 100 | 5.5 |
| 02:09 ET | 400 | 5.515 |
| 02:12 ET | 100 | 5.515 |
| 02:16 ET | 200 | 5.53 |
| 02:20 ET | 3867 | 5.5 |
| 02:36 ET | 100 | 5.51 |
| 02:39 ET | 100 | 5.515 |
| 02:41 ET | 100 | 5.5 |
| 02:48 ET | 883 | 5.525 |
| 02:50 ET | 601 | 5.51 |
| 02:54 ET | 1220 | 5.49 |
| 02:57 ET | 100 | 5.51 |
| 03:03 ET | 167 | 5.51 |
| 03:08 ET | 100 | 5.53 |
| 03:10 ET | 100 | 5.51 |
| 03:12 ET | 100 | 5.49 |
| 03:17 ET | 2730 | 5.495 |
| 03:19 ET | 400 | 5.485 |
| 03:28 ET | 743 | 5.51 |
| 03:30 ET | 895 | 5.53 |
| 03:32 ET | 200 | 5.535 |
| 03:35 ET | 459 | 5.52 |
| 03:37 ET | 615 | 5.52 |
| 03:44 ET | 255 | 5.51 |
| 03:46 ET | 300 | 5.52 |
| 03:48 ET | 5660 | 5.55 |
| 03:50 ET | 237 | 5.5599 |
| 03:51 ET | 100 | 5.56 |
| 03:53 ET | 100 | 5.56 |
| 03:55 ET | 844 | 5.58 |
| 03:57 ET | 1350 | 5.56 |
| 04:00 ET | 22756 | 5.57 |
Nov 13, 2024
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Design Therapeutics Inc | 315.4M | -6.6x | --- |
Kodiak Sciences Inc | 310.4M | -1.6x | --- |
Compass Pathways PLC | 304.5M | -2.0x | --- |
Jasper Therapeutics Inc | 327.6M | -4.6x | --- |
Nautilus Biotechnology Inc | 298.8M | -4.2x | --- |
Q32 Bio Inc | 329.4M | -3.6x | --- |
Company Information
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Contact Information
- Headquarters
- 6005 Hidden Valley Road, Suite 110CARLSBAD, CA, United States 92011
- Phone
- 858-293-4900
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
- Pratik Shah
- Chief Operating Officer
- Sean Jeffries
- Chief Medical Officer
- Jae Kim
- Lead Independent Director
- Simeon George
- Independent Director
- Heather Berger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $315.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 56.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.84 |
EPS | $-0.85 |
Book Value | $4.92 |
P/E Ratio | -6.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
